Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Of the 944 clinical cases, 13.0% were characterized as probable LATE (2.4% pure LATE and 10.6% LATE+AD) and 23.7% were characterized as probable AD without LATE. MRI volumetry revealed that the medial temporal lobe was most affected in pure LATE cases (P < 0.001), whereas the orbitofrontal gyrus and lateral temporal lobe were most vulnerable in mixed LATE+AD cases (P = 0.001; P < 0.001). Post hoc analysis identified the entorhinal cortex and amygdala as key regions for distinguishing mixed LATE+AD cases from pure LATE and pure AD cases, respectively (P = 0.05; P < 0.001). Subgroup analysis of the probable LATE+AD group demonstrated additive or synergistic effects of both pathologies, with three quarters of cases exhibiting concordant lateralized metabolic brain changes, predominantly left-sided, based on LATE and AD z score products (P < 0.001). A similar pattern of left-dominant brain atrophy was observed in MRI volumetry. Substantial numbers of our patients exhibited LATE features that were characterized objectively using scans from autopsy-proven cases. These LATE cases were associated with specific regional atrophy measured by quantitative MRI. Cases with LATE+AD copathologies demonstrated synergistic hemispheric involvement. Further investigations of such synergistic changes between LATE and AD are warranted.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ngam, P. I., Anzai, Y., Brown, C. J. C., Frost, N. A., Sorweid, M. K., Thientunyakit, T., et al. (2026). Copathologies of Limbic-Predominant Age-Related TDP-43 Encephalopathy and Alzheimer Disease: [ 18 F]FDG PET Statistical Mapping and Quantitative MRI Volumetry. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270614

Vancouver

Ngam PI, Anzai Y, Brown CJC, Frost NA, Sorweid MK, Thientunyakit T, et al. Copathologies of Limbic-Predominant Age-Related TDP-43 Encephalopathy and Alzheimer Disease: [ 18 F]FDG PET Statistical Mapping and Quantitative MRI Volumetry. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270614. PMID: 41571430.

BibTeX

@article{ngam2026-41571430,
  author  = {Ngam, Pei Ing and Anzai, Yoshimi and Brown, Christine J. Cliatt and Frost, Nicholas Alonzo and Sorweid, Michelle Keown and Thientunyakit, Tanyaluck and Minoshima, Satoshi and {Alzheimer’s Disease Neuroimaging Initiative}},
  title   = {{Copathologies of Limbic-Predominant Age-Related TDP-43 Encephalopathy and Alzheimer Disease: [ 18 F]FDG PET Statistical Mapping and Quantitative MRI Volumetry}},
  journal = {Journal of Nuclear Medicine},
  year    = {2026},
  doi     = {10.2967/jnumed.125.270614},
  pmid    = {41571430},
  url     = {https://doi.org/10.2967/jnumed.125.270614}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

Among 944 clinical cases, scans showed that pure LATE mainly affected the medial temporal lobe, while mixed LATE plus Alzheimer's disease affected the orbitofrontal and lateral temporal regions, with some cases showing combined effects of both pathologies. The authors say these findings help characterize LATE features objectively using scans from autopsy-proven cases, and that further investigation of the combined effects is warranted.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Nuclear Medicine)
Journal's citation record 2 / 4 Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 944 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 9.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author for the Alzheimer’s Disease Neuroimaging Initiative: h-index 12 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Utah: institution h-index 1,238 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41571430)
Free to read 2 / 2 Free to read
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Biomarkers

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →